{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:33:10Z","timestamp":1782271990599,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.josat.2025.209879","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T06:33:48Z","timestamp":1767508428000},"page":"209879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Buprenorphine dosing patterns and treatment outcomes for patients with opioid use disorder insured by Medicaid in Philadelphia"],"prefix":"10.1016","volume":"183","author":[{"given":"Rachel","family":"French","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Lorenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatoyin","family":"Fadeyibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jewell","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suet","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Altman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Candon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.josat.2025.209879_bb0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/JCP.0000000000001308","article-title":"Treatment of opioid use disorder attributed to fentanyl with high-dose buprenorphine: a case report","volume":"41","author":"Baca-Atlas","year":"2021","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1016\/j.josat.2025.209879_bb0010","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jsat.2014.09.007","article-title":"Buprenorphine\/naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder","volume":"48","author":"Becker","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"9","key":"10.1016\/j.josat.2025.209879_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/15265161.2021.1915411","article-title":"Health disparities, systemic racism, and failures of cultural competence","volume":"21","author":"Berger","year":"2021","journal-title":"The American Journal of Bioethics"},{"issue":"9","key":"10.1016\/j.josat.2025.209879_bb0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2025.209879_bb0025","series-title":"Fentanyl in the US heroin supply: A rapidly changing risk environment","author":"Ciccarone","year":"2017"},{"key":"10.1016\/j.josat.2025.209879_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108146","article-title":"A systematic review of patients\u2019 and providers\u2019 perspectives of medications for treatment of opioid use disorder","volume":"119","author":"Cioe","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"12","key":"10.1016\/j.josat.2025.209879_bb0035","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/pme.12520","article-title":"Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients","volume":"15","author":"Daitch","year":"2014","journal-title":"Pain Medicine"},{"key":"10.1016\/j.josat.2025.209879_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109097","article-title":"Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies","volume":"228","author":"De Aquino","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.josat.2025.209879_bb0045","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: A systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"The Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.josat.2025.209879_bb0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/10550887.2011.642758","article-title":"Effect of buprenorphine dose on treatment outcome","volume":"31","author":"Fareed","year":"2012","journal-title":"Journal of Addictive Diseases"},{"issue":"2","key":"10.1016\/j.josat.2025.209879_bb0055","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1176\/appi.ajp.2021.21040381","article-title":"Surging racial disparities in the US overdose crisis","volume":"179","author":"Friedman","year":"2022","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.josat.2025.209879_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13722-019-0139-3","article-title":"Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence","volume":"14","author":"Godersky","year":"2019","journal-title":"Addiction Science & Clinical Practice"},{"issue":"4","key":"10.1016\/j.josat.2025.209879_bb0065","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s40615-022-01384-6","article-title":"The opioid epidemic: A crisis disproportionately impacting black Americans and urban communities","volume":"10","author":"Gondr\u00e9-Lewis","year":"2023","journal-title":"Journal of Racial and Ethnic Health Disparities"},{"issue":"5","key":"10.1016\/j.josat.2025.209879_bb0070","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ADM.0000000000001189","article-title":"Evidence on buprenorphine dose limits: A review","volume":"17","author":"Grande","year":"2023","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.josat.2025.209879_bb0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/add.16646","article-title":"Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: A systematic review","volume":"120","author":"Gregory","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2025.209879_bb0080","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2147\/JPR.S305146","article-title":"Benefit-risk analysis of buprenorphine for pain management","author":"Hale","year":"2021","journal-title":"Journal of Pain Research"},{"issue":"10","key":"10.1016\/j.josat.2025.209879_bb0085","doi-asserted-by":"crossref","first-page":"e2129409","DOI":"10.1001\/jamanetworkopen.2021.29409","article-title":"Trends in and characteristics of buprenorphine misuse among adults in the US","volume":"4","author":"Han","year":"2021","journal-title":"JAMA Network Open"},{"issue":"7","key":"10.1016\/j.josat.2025.209879_bb0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1016\/j.josat.2025.209879_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4996","article-title":"Overcoming barriers to prescribing buprenorphine in the emergency department","volume":"3","author":"Kim","year":"2020","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.josat.2025.209879_bb0100","article-title":"A systematic review of the effectiveness of buprenorphine for opioid use disorder compared to other treatments: Implications for research and practice","volume":"10","author":"Mariolis","year":"2019","journal-title":"Journal of Addiction Research & Therapy"},{"issue":"3","key":"10.1016\/j.josat.2025.209879_bb0105","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jama.2019.18913","article-title":"Trends in buprenorphine treatment in the United States, 2009-2018","volume":"323","author":"Olfson","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.josat.2025.209879_bb3105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.36612","article-title":"Variation in opioid agonist dosing in clinical trials by race and ethnicity","volume":"7","author":"Ross","year":"2024","journal-title":"JAMA Network Open"},{"issue":"6","key":"10.1016\/j.josat.2025.209879_bb0110","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: An overview","volume":"33","author":"Shulman","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.josat.2025.209879_bb0115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: Buprenorphine experiences in an era of illicit fentanyl","volume":"74","author":"Silverstein","year":"2019","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2025.209879_bb0120","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"bmj"},{"issue":"6","key":"10.1016\/j.josat.2025.209879_bb0125","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/add.70002","article-title":"The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021","volume":"120","author":"Stringfellow","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2025.209879_bb0130","author":"US Food & Drug Administration"},{"issue":"12","key":"10.1016\/j.josat.2025.209879_bb0135","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/M15-2234","article-title":"Early coverage, access, utilization, and health effects associated with the affordable care act medicaid expansions: A quasi-experimental study","volume":"164","author":"Wherry","year":"2016","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1016\/j.josat.2025.209879_bb0140","first-page":"313","article-title":"Buprenorphine therapy for opioid use disorder","volume":"97","author":"Zoorob","year":"2018","journal-title":"American Family Physician"},{"issue":"6","key":"10.1016\/j.josat.2025.209879_bb0145","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/ADM.0000000000000789","article-title":"Discontinuing methadone and buprenorphine: A review and clinical challenges","volume":"15","author":"Zweben","year":"2021","journal-title":"Journal of Addiction Medicine"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925002589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925002589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:13:00Z","timestamp":1778937180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875925002589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":30,"alternative-id":["S2949875925002589"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2025.209879","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine dosing patterns and treatment outcomes for patients with opioid use disorder insured by Medicaid in Philadelphia","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2025.209879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209879"}}